Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from Race Oncology Ltd. ( (AU:RAC) ) is now available.
Race Oncology Ltd has announced its Annual General Meeting (AGM) will be held on November 24, 2025, at the State Library NSW in Sydney, with director nominations closing on October 13, 2025. This announcement is a procedural update for stakeholders, emphasizing the company’s governance and operational planning, which may impact its strategic direction and leadership structure.
More about Race Oncology Ltd.
Race Oncology (ASX: RAC) is an ASX-listed clinical stage biopharmaceutical company focused on cancer care. Its lead asset, RCDS1 (E,E-bisantrene), is an anticancer agent with demonstrated therapeutic activity and a well-characterized safety profile. The company is advancing a proprietary formulation, RC220, targeting unmet needs in oncology, particularly in combination with doxorubicin for enhanced anticancer activity and cardioprotection. Race Oncology collaborates with various institutions and is exploring partnerships to expand access to RC220 globally.
Average Trading Volume: 342,514
Technical Sentiment Signal: Buy
Current Market Cap: A$690.1M
For an in-depth examination of RAC stock, go to TipRanks’ Overview page.